About us
Principles
Start with nature.
We take a protein the body already uses to protect tissue and engineer it to work harder.
Independent by design.
We are funded by individual investors, not venture capital or big pharma.
Show our work.
We share progress openly, including when plans change.
Our story
Dr. Gaetano Scuderi noticed that some patients got worse after spine surgery with no sign of infection. He suspected that proteases, enzymes that normally clear damaged tissue, were staying switched on and damaging cartilage.
His discovery of the fibronectin-aggrecan complex (FAC), a marker of protease-driven cartilage breakdown, supported that idea. Searching for a way to block many proteases at once, he found alpha-2-macroglobulin (A2M), a natural protease inhibitor in the blood.
That led first to APIC™, which concentrates a patient’s own A2M, and then to CYT-108, an engineered version designed for consistency and scale. From 2010 to 2012, our research was also supported by a $1.8 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health.
$40.3M
Funding raised including
$25M+ through equity crowdfunding
Founded:
2006
Location:
Jupiter, Florida
PARTNERED WITH RESEARCHERS FROM
Milestones
2006
Founded as Gamma Spine. Renamed Cytonics Corporation in 2007.
2013
APIC™ receives FDA 510(k) clearance.
2014–2015
APIC™ licensed internationally. Work on CYT-108 begins.
2016–2017
First GMP-grade CYT-108 produced.
2018
Joey Bose appointed CEO.
2019
First equity crowdfunding offering (SeedInvest Reg CF).
2019–2020
Preclinical studies completed. APIC™ licensed for veterinary use.
2021
First Regulation A+ offering (SeedInvest). 2022: Reg CF offering on SeedInvest. About $9M across the two. IND-enabling studies completed.
2023–2024
Reg CF offerings on DealMaker and StartEngine. First patient dosed with CYT-108 in June 2024.
2025
Acquired a 5,000-patient osteoarthritis dataset and began building FOCAL, an AI model of how OA progresses. Phase 1 database locked in October. Largest single raise to date: a Reg A+ offering on StartEngine.
2026
Phase 1 Clinical Study Report completed in March. Reg CF offering on DealMaker.
Leadership
Board of Directors
Medical Advisors
Our Ambassadors
Investor Presentation
Cytonics: a biotech rebellion
Get updates on CYT-108 and the science behind it.

The company is “testing the waters” of a potential offering which will be conducted under a valid exemption under U.S. Securities laws. No money or other consideration is being solicited, and if sent in response, will not be accepted. Reservations and/or indications of interest involve no obligation or commitment of any kind on any party. This process allows companies to determine whether there may be interest in an eventual offering of its securities. The company is not under any obligation to make an offering. It may choose to make an offering to some, but not all, of the people who indicate an interest in investing. If the company does go ahead with an offering, it will only be able to make sales after it has filed offering documents with the Securities and Exchange Commission (SEC). The information in those offering documents will be more complete than the information the company is providing now, and could differ in important ways. You must read the documents filed with the SEC before investing.
This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
© 2026 Cytonics Corporation. All rights reserved.



















